- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07392892
Een onderzoek naar het studiemedicijn PF-08634404 in combinatie met chemotherapie bij gastro-oesofageale kanker
EEN FASE 2/3 INTERVENTIONELE STUDIE VAN PF-08634404 IN COMBINATIE MET CHEMOTHERAPIE BIJ BEHANDELINGSNAÏEVE DEELNEMERS MET LOKAAL GEVORDERDE OF METASTATISCHE MAAG-, MAAG-SLOKDARMJUNCTIE- OF SLOKDARMADENOCARCINOOM
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.
The study has two parts:
- In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
- In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.
The treatment will be given in repeated time periods called cycles.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Pfizer CT.gov Call Center
- Telefoonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studie Locaties
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Nog niet aan het werven
- London Health Sciences Centre - Verspeeten Family Cancer Centre
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510655
- Werving
- The Sixth Affiliated hospital, Sun Yat-sen University
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Werving
- Hubei Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200031
- Werving
- Zhongshan Hospital,Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Werving
- Sichuan Cancer hospital
-
-
-
-
-
Paris, Frankrijk, 75015
- Werving
- Hôpital Européen Georges Pompidou
-
-
-
-
Central District
-
Petah Tikva, Central District, Israël, 4941492
- Werving
- Rabin Medical Center
-
-
HA Merkaz
-
Ramat Gan, HA Merkaz, Israël, 5265601
- Werving
- Sheba Medical Center
-
-
TELL ABĪB
-
Tel Aviv, TELL ABĪB, Israël, 6423906
- Werving
- Sourasky Medical Center
-
-
-
-
-
Milan, Italië, 20141
- Werving
- Istituto Europeo di Oncologia IRCCS
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Werving
- Aichi Cancer Center
-
-
-
-
-
Bayamón, Puerto Rico, 00959
- Werving
- Pan American Center for Oncology Trials, LLC - Bayamón Office
-
-
United States
-
Manati, United States, Puerto Rico, 00674
- Werving
- Pan American Center for Oncology Trials, LLC - Manati Office
-
-
-
-
Barcelona [barcelona]
-
Barcelona, Barcelona [barcelona], Spanje, 08035
- Werving
- Hospital Universitari Vall d'Hebron
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanje, 28041
- Werving
- Hospital Universitario 12 de Octubre
-
-
Ourense [orense]
-
Ourense, Ourense [orense], Spanje, 32005
- Nog niet aan het werven
- Complexo Hospitalario Universitario de Ourense
-
-
-
-
-
Tainan, Taiwan, 704302
- Werving
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10002
- Werving
- National Taiwan University Hospital
-
Taipei, Taiwan, 11217
- Werving
- Taipei Veterans General Hospital
-
-
-
-
California
-
Atascadero, California, Verenigde Staten, 93422
- Werving
- UCLA Hematology/Oncology - Atascadero
-
Burbank, California, Verenigde Staten, 91505
- Werving
- UCLA Hematology/Oncology - Burbank
-
Encino, California, Verenigde Staten, 91436
- Werving
- UCLA Hematology/Oncology - Encino
-
Marina del Rey, California, Verenigde Staten, 90292
- Werving
- UCLA Hematology/Oncology - Marina del Rey
-
Porter Ranch, California, Verenigde Staten, 91326
- Werving
- UCLA Hematology/Oncology - Porter Ranch
-
San Francisco, California, Verenigde Staten, 94158
- Nog niet aan het werven
- UCSF Helen Diller Family Comprehensive Cancer Center
-
San Francisco, California, Verenigde Staten, 94158
- Nog niet aan het werven
- UCSF Investigational Drugs Pharmacy
-
San Luis Obispo, California, Verenigde Staten, 93401
- Werving
- UCLA Hematology/Oncology - San Luis Obispo
-
Santa Barbara, California, Verenigde Staten, 93101
- Werving
- UCLA Hematology/Oncology - Santa Barbara
-
Santa Monica, California, Verenigde Staten, 90404
- Werving
- UCLA Hematology/Oncology - Santa Monica
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80012
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Boulder, Colorado, Verenigde Staten, 80303
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Centennial, Colorado, Verenigde Staten, 80112
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Verenigde Staten, 80907
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Verenigde Staten, 80923
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Verenigde Staten, 80218
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Verenigde Staten, 80220
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Englewood, Colorado, Verenigde Staten, 80113
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Lakewood, Colorado, Verenigde Staten, 80228
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Littleton, Colorado, Verenigde Staten, 80120
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Lone Tree, Colorado, Verenigde Staten, 80124
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Longmont, Colorado, Verenigde Staten, 80504
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Pueblo, Colorado, Verenigde Staten, 81003
- Werving
- Rocky Mountain Cancer Centers, LLP
-
Thornton, Colorado, Verenigde Staten, 80260
- Werving
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Daytona Beach, Florida, Verenigde Staten, 32117
- Nog niet aan het werven
- Florida Cancer Specialists
-
Fleming Island, Florida, Verenigde Staten, 32003
- Nog niet aan het werven
- Florida Cancer Specialists
-
Palm Beach Gardens, Florida, Verenigde Staten, 33410
- Nog niet aan het werven
- Florida Cancer Specialists
-
Sebring, Florida, Verenigde Staten, 33870
- Nog niet aan het werven
- Florida Cancer Specialists
-
Wellington, Florida, Verenigde Staten, 33414
- Nog niet aan het werven
- Florida Cancer Specialists
-
West Palm Beach, Florida, Verenigde Staten, 33401
- Nog niet aan het werven
- Florida Cancer Specialists
-
-
Illinois
-
Arlington Heights, Illinois, Verenigde Staten, 60005
- Werving
- Illinois Cancer Specialists
-
Bloomington, Illinois, Verenigde Staten, 61704
- Werving
- Illinois CancerCare - Bloomington
-
Chicago, Illinois, Verenigde Staten, 60631
- Werving
- Illinois Cancer Specialists
-
Galesburg, Illinois, Verenigde Staten, 61401
- Werving
- Illinois CancerCare - Galesburg
-
Niles, Illinois, Verenigde Staten, 60714
- Werving
- Illinois Cancer Specialists
-
Ottawa, Illinois, Verenigde Staten, 61350
- Werving
- Illinois CancerCare-Ottawa-Fox River Cancer Center
-
Pekin, Illinois, Verenigde Staten, 61554
- Werving
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Verenigde Staten, 61615
- Werving
- Illinois CancerCare, P.C.
-
Peru, Illinois, Verenigde Staten, 61354
- Werving
- Illinois CancerCare-Peru - Valley Regional Cancer Center
-
Washington, Illinois, Verenigde Staten, 61571
- Werving
- Illinois CancerCare-Washington
-
-
Maryland
-
Annapolis, Maryland, Verenigde Staten, 21401
- Werving
- Maryland Oncology Hematology, P.A.
-
Bethesda, Maryland, Verenigde Staten, 20817
- Werving
- Maryland Oncology Hematology, P.A.
-
Brandywine, Maryland, Verenigde Staten, 20613
- Werving
- Maryland Oncology Hematology, P.A.
-
Columbia, Maryland, Verenigde Staten, 21044
- Werving
- Maryland Oncology Hematology, P.A.
-
Germantown, Maryland, Verenigde Staten, 20876
- Werving
- Maryland Oncology Hematology, P.A.
-
Largo, Maryland, Verenigde Staten, 20774
- Werving
- Maryland Oncology Hematology, P.A.
-
Rockville, Maryland, Verenigde Staten, 20850
- Werving
- Maryland Oncology Hematology, P.A.
-
Silver Spring, Maryland, Verenigde Staten, 20904
- Werving
- Maryland Oncology Hematology, P.A.
-
-
Nevada
-
Reno, Nevada, Verenigde Staten, 89502
- Werving
- Renown Regional Medical Center
-
Reno, Nevada, Verenigde Staten, 89502
- Werving
- Renown Health Medical Oncology
-
Reno, Nevada, Verenigde Staten, 89502
- Werving
- Renown Office of Clinical Research
-
-
New Jersey
-
Morristown, New Jersey, Verenigde Staten, 07960
- Nog niet aan het werven
- Atlantic Health System
-
Summit, New Jersey, Verenigde Staten, 07901
- Nog niet aan het werven
- Atlantic Health System / Overlook Medical Center
-
-
New York
-
Long Island City, New York, Verenigde Staten, 11101
- Werving
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
-
Long Island City, New York, Verenigde Staten, 11101
- Werving
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
-
New York, New York, Verenigde Staten, 10065
- Werving
- Memorial Sloan Kettering Cancer Center - Main Campus
-
New York, New York, Verenigde Staten, 10021
- Werving
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
New York, New York, Verenigde Staten, 10022
- Werving
- Rockefeller Outpatient Pavilion (53rd Street)
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45245
- Werving
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Verenigde Staten, 45242
- Werving
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Verenigde Staten, 45211
- Werving
- Oncology Hematology Care Clinical Trials, LLC
-
Fairfield, Ohio, Verenigde Staten, 45014
- Werving
- Oncology Hematology Care Clinical Trials, LLC
-
-
Pennsylvania
-
Bensalem, Pennsylvania, Verenigde Staten, 19020
- Werving
- Alliance Cancer Specialists, PC
-
Doylestown, Pennsylvania, Verenigde Staten, 18901
- Werving
- Alliance Cancer Specialists, PC
-
Horsham, Pennsylvania, Verenigde Staten, 19044
- Werving
- Alliance Cancer Specialists, PC
-
Langhorne, Pennsylvania, Verenigde Staten, 19047
- Werving
- Alliance Cancer Specialists, PC
-
Media, Pennsylvania, Verenigde Staten, 19063
- Werving
- Alliance Cancer Specialists, PC
-
Sellersville, Pennsylvania, Verenigde Staten, 18960
- Werving
- Alliance Cancer Specialists, PC
-
Wynnewood, Pennsylvania, Verenigde Staten, 19096
- Werving
- Alliance Cancer Specialists, PC
-
-
Texas
-
Irving, Texas, Verenigde Staten, 75063
- Werving
- US Oncology Investigational Products Center (IPC)
-
-
Virginia
-
Arlington, Virginia, Verenigde Staten, 22201
- Werving
- Virginia Cancer Specialists, PC
-
Chesapeake, Virginia, Verenigde Staten, 23320
- Werving
- Virginia Oncology Associates
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- Virginia Cancer Specialists, PC
-
Hampton, Virginia, Verenigde Staten, 23666
- Werving
- Virginia Oncology Associates
-
Manassas, Virginia, Verenigde Staten, 20110
- Werving
- Virginia Cancer Specialists, PC
-
Newport News, Virginia, Verenigde Staten, 23606
- Werving
- Virginia Oncology Associates
-
Norfolk, Virginia, Verenigde Staten, 23502
- Werving
- Virginia Oncology Associates
-
Reston, Virginia, Verenigde Staten, 20190
- Werving
- Virginia Cancer Specialists, PC
-
Virginia Beach, Virginia, Verenigde Staten, 23456
- Werving
- Virginia Oncology Associates
-
Woodbridge, Virginia, Verenigde Staten, 22191
- Werving
- Virginia Cancer Specialists, PC
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98195
- Werving
- University of Washington Medical Center
-
Seattle, Washington, Verenigde Staten, 98109
- Werving
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Verenigde Staten, 98104
- Werving
- Harborview Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
- Evidence of locally advanced or metastatic disease.
- Eastern Cooperative Oncology Group performance status (ECOG) 0-1
- No prior systemic therapy for advanced or metastatic disease.
- Adequate hepatic, liver, and renal function
- HER-2 negative status based on local testing
- PD-L1 positive status based on local testing
Exclusion Criteria:
- Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
- Clinically significant risk of hemorrhage or fistula
- Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
- Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
- Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Phase 2 Portion
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Andere namen:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Experimenteel: Phase 3: Arm A
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Andere namen:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Actieve vergelijker: Phase 3: Arm B
Nivolumab + Chemotherapy |
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. Participants will receive Nivolumab intravenously. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Tijdsspanne: Approximately 4 years
|
Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 2: Number of participants with treatment-emergent adverse events
Tijdsspanne: Through 90 days after the last study intervention; Approximately 4 years
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Tijdsspanne: Approximately 4 years
|
PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: Overall Survival (OS)
Tijdsspanne: Approximately 4 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Approximately 4 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Fase 2: Incidentie van Anti-Medicijn Antilichamen (ADA) tegen PF-08634404
Tijdsspanne: Ongeveer 21 maanden
|
Ongeveer 21 maanden
|
|
|
Fase 3: Incidentie van ADA tegen PF-08634404
Tijdsspanne: Ongeveer 21 maanden
|
Ongeveer 21 maanden
|
|
|
Fase 3: Verandering ten opzichte van de baseline in de totale score van de Functionele Evaluatie van Kanker Therapie - Maag (FACT-Ga)
Tijdsspanne: Ongeveer 4 jaar
|
Ongeveer 4 jaar
|
|
|
Fase 3: Tijd tot definitieve verslechtering in FACT-Ga Totale score
Tijdsspanne: Ongeveer 4 jaar
|
Ongeveer 4 jaar
|
|
|
Fase 3: Tijd tot definitieve verslechtering van de Gastric Cancer Subscale (GaCS)-score
Tijdsspanne: Ongeveer 4 jaar
|
Ongeveer 4 jaar
|
|
|
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Tijdsspanne: Approximately 4 years
|
DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Tijdsspanne: Approximately 4 years
|
PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Overall Survival (OS)
Tijdsspanne: Approximately 4 years
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 4 years
|
|
Phase 2: Number of participants with laboratory abnormalities
Tijdsspanne: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 2: Serum concentrations of PF-08634404
Tijdsspanne: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
|
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Tijdsspanne: Approximately 4 years
|
ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR. |
Approximately 4 years
|
|
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Tijdsspanne: Approximately 4 years
|
ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Tijdsspanne: Approximately 4 years
|
PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Tijdsspanne: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Tijdsspanne: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Tijdsspanne: Approximately 4 years
|
PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: Number of participants with treatment-emergent adverse events
Tijdsspanne: Through 90 days after the last study intervention; Approximately 4 years
|
AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s) |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Number of participants with laboratory abnormalities
Tijdsspanne: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Serum concentrations of PF-08634404
Tijdsspanne: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Pfizer CT.gov Call Center, Pfizer
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Maag Ziekten
- Maagneoplasmata
- Adenocarcinoom van de slokdarm
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Therapeutica
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Nivolumab
- Drugstherapie
Andere studie-ID-nummers
- C6461016
- 2025-524717-86-00 (Register-ID: CTIS (EU))
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .